Sex: Male
Histology: Adenocarcinoma
Key Mutations: EML4-ALK Fusion
Molecular Characteristics: Yes
Matched Normal: Yes
Treatment: crizotinib
Site: Lung
Paired: No
Comments: crizotinib resistant
Licensing Information: Corporations and other for-profit entities may nonexclusively license Memorial Sloan Kettering’s tangible materials for research or commercial purposes. For more information, please contact TRMOTDRTM@mskcc.org.
Stage of Development
Ready to use